Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

Given intravenously (IV)

Given IV

Given Orally (PO)

Undergo regular care imaging/scans

Blood and tissue samples

ClonoSEQ is an FDA-cleared, Clinical Laboratory Improvement Amendments of 1988 (CLIA)-validated measure used to determine minimal residual disease (MRD). This helps uncover how much, if any, cancer remains in your body during and after treatment.

Undergo bone marrow biopsy and aspiration.